Key facts
- Invus Global Management, LLC filed SCHEDULE 13G/A for Neumora Therapeutics, Inc. Common Stock, par value $0.0001 per share (NMRA).
- Disclosed ownership: 4.7%.
- Date of event: 31 Mar 2026.
Invus Global Management, LLC - 31 Mar 2026 SCHEDULE 13G/A Report for Neumora Therapeutics, Inc. Common Stock, par value $0.0001 per share (NMRA)
- Filing Manager
- Invus Global Management, LLC
- Reporting Manager
- Raymond Debbane
- Symbol
- NMRA
- Shares outstanding
- 180,804,723 shares
- Disclosed Ownership
- 8,497,822 shares
- Ownership
- 4.7%
- Form type
- SCHEDULE 13G/A
- Filing time
- 04 May 2026, 14:08:16 UTC
- Date of event
- 31 Mar 2026
- Previous filing
- 19 Feb 2026
- SEC
- View on sec.gov
Key filing fact
Invus Global Management, LLC disclosed 4.7% ownership in Neumora Therapeutics, Inc. Common Stock, par value $0.0001 per share (NMRA) on 31 Mar 2026.
Change
- Previous schedule filing date: 19 Feb 2026.
- Current filing was accepted on 04 May 2026, 14:08.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (8)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 4.3% | 7,740,030 | 7,740,030 | 0 | /s/ Raymond Debbane | Raymond Debbane, President of Invus Public Equities Advisors, LLC, its general partner | |
| Invus Public Equities Advisors, LLC | 4.3% | 7,740,030 | 7,740,030 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Invus Global Management, LLC | 4.3% | 7,740,030 | 7,740,030 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Siren, L.L.C. | 4.3% | 7,740,030 | 7,740,030 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Avicenna Life Sci Master Fund LP | 0.4% | 757,792 | 757,792 | 0 | /s/ Raymond Debbane | Raymond Debbane, Chief Executive Officer of Avicenna Life Sci Master GP LLC, its general partner | |
| Avicenna Life Sci Master GP LLC | 0.4% | 757,792 | 757,792 | 0 | /s/ Raymond Debbane | Raymond Debbane, Chief Executive Officer | |
| Ulys, L.L.C. | 0.4% | 757,792 | 757,792 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Raymond Debbane | 4.7% | 8,497,822 | 8,497,822 | 0 | /s/ Raymond Debbane | Raymond Debbane |
CIK / CUSIP context first